First Patient Enrolled In Thrombolex’s RESCUE II Study – On-Table Pharmacomechanical Lysis Without Post-Procedural Infusion
Thrombolex, Inc. announced the enrollment of the first patient in the RESCUE II study using the BASHIR™ Endovascular Catheter for the treatment of acute intermediate-risk pulmonary embolism by Drs. Riyaz Bashir and Vladimir Lakhter, at Temple University Hospital, Philadelphia, Pennsylvania. - January 22, 2024
Thrombolex, Inc. Announces the New Bashir™ .035 Endovascular Catheters
Thrombolex, Inc., announces an expansion of the existing product line with the new BASHIR™ .035 and BASHIR™ S-B .035 Endovascular Catheters, which are comparable with an 0.035” guidewire. The BASHIR™ and BASHIR™ S-B Endovascular Catheters are 510(k) cleared for the treatment of acute pulmonary embolism (PE). - January 09, 2024
Thrombolex Announces Significant New Insights from the RESCUE Trial with the BASHIR™ Endovascular Catheter
Thrombolex, Inc., announced never-before-reported major reductions in obstruction in all of the segmental pulmonary arteries (PA), based on independent core lab data analysis of 107 patients from 18 sites in the USA, with acute intermediate-risk pulmonary embolism (PE), using the BASHIR™ Endovascular Catheter and small doses of tPA. The RESCUE trial also showed unsurpassed efficacy and safety in this patient population compared to recently published studies with other FDA-cleared devices. - October 24, 2023
Thrombolex, Inc. Has Received FDA Clearance for Use of BASHIR™ Endovascular Catheters for Treatment of Acute Pulmonary Embolism
Thrombolex, Inc. has received 510(k) clearance for use of the BASHIR™ and BASHIR™ S-B Endovascular Catheters for the treatment of acute pulmonary embolism (PE). - April 20, 2023
Marked Reduction in Segmental and Main Pulmonary Artery Occlusions Shown in NIH-Sponsored RESCUE trial with the BASHIR™ Endovascular Catheter
Marked reduction in segmental and main pulmonary artery occlusions shown in NIH-sponsored RESCUE trial with the BASHIR™ Endovascular Catheter in Patients with Intermediate Risk Acute Pulmonary Embolism. - March 06, 2023
Thrombolex, Inc. Awarded 2-Year Agreement with Premier, Inc. for Hybrid Endovascular Catheter for the Treatment of VTE
Thrombolex, Inc. has been awarded a group purchasing agreement with Premier Inc., effective December 1, 2022. The new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for the BASHIR™ Endovascular Catheters. The... - December 15, 2022
Thrombolex Announces Publication in the Journal of the American College of Cardiology, Cardiovascular Interventions
Thrombolex Releases the Results of the RESCUE Pivotal Trial for the Treatment of Acute Pulmonary Embolism (PE) with the BASHIR™ Endovascular Catheter. - December 08, 2022
Michael Cerminaro to Succeed Marvin Woodall as CEO of Thrombolex Woodall to Remain Executive Chairman of the Board of Directors
Thrombolex today announced that its Board of Directors has named Michael Cerminaro Chief Executive Officer (CEO) of Thrombolex effective July 13, 2022, the date of the Company’s most recent Quarterly Board Meeting. Mr. Cerminaro will also retain his current title of President. Mr. Woodall,... - July 18, 2022
Thrombolex, Inc. – BASHIR™ Endovascular Catheters Show Dramatic Reduction in Thromboembolic Occlusions
Thrombolex, Inc. – BASHIR™ Endovascular Catheters Show Dramatic Reduction in Thromboembolic Occlusions in Segmental Pulmonary Arteries of Patients with Acute Intermediate Risk PE: Interim Results of NIH-Funded RESCUE Trial - January 17, 2022
Thrombolex, Inc. - DVT Results with the Bashir™ Catheter.
The BASHIR™ Endovascular Catheter (BEC) and the BASHIR™ Plus Endovascular Catheters (BASHIR™+ 10, BASHIR™+20, BASHIR™+30, BASHIR™+40) are hybrid devices that enable both mechanical and pharmacological treatment through use of an expandable infusion basket with... - October 14, 2021
Thrombolex, Inc. – Interim Results of NIH-Funded RESCUE Trial
Thrombolex, Inc. – BASHIR™ Endovascular Catheter Shows Marked Reduction in RV/LV Ratio and Thrombus Burden in Patients with Acute Intermediate-Risk PE - October 06, 2021
Thrombolex, Inc. – RESCUE Trial Interim Data Presented at VIVA
Thrombolex, Inc. continues to enroll in the pivotal RESCUE trial for the treatment of patients with acute submassive pulmonary embolism (PE). This trial is conducted using the BASHIR™ and BASHIR™ S-B Endovascular Catheters (BEC) under an Investigational Device Exemption (IDE) from the... - September 29, 2021
THROMBOLEX, Inc. – Attendance at VIVA & VEINS
THROMBOLEX, Inc. will be attending the VEINS Conference (Booth T8) and VIVA Physicians Conference (Booth #502) in Las Vegas, NV October 3-7. - September 16, 2021
THROMBOLEX™ Inc. First Patient Enrolled in the RESCUE Trial for Treatment of Acute Submassive Pulmonary Embolism
THROMBOLEX™ Inc. has announced that it has enrolled the first patient in its pivotal RESCUE trial for the treatment of patients with acute submassive pulmonary embolism (PE) using the BASHIR® Endovascular Catheter, under an Investigational Device Exemption (IDE) from the FDA. RESCUE is a... - August 06, 2020
THROMBOLEX™ Inc. Receives $3 million Small Business Innovation Research (SBIR) Grant from the NIH to Fund the RESCUE Trial
Thrombolex™ Inc. has announced that it was awarded a $3 million Small Business Innovation Research (SBIR) grant from the National Heart, Lung and Blood Institute (NHLBI) section of the NIH to fund their pivotal RESCUE trial under an IDE for the treatment of up to 125 patients with acute,... - July 07, 2020
Thrombolex Bashir® Endovascular Catheter First-In-Man (FIM) Trial for Acute Pulmonary Embolism
Thrombolex Bashir® Endovascular Catheter First-In-Man (FIM) Trial for Acute Pulmonary Embolism Confirms Early Safety and Feasibility and Impressive Reduction of Clot Burden - Results of FIM Trial presented at American Venous Forum (AVF) Annual Meeting - March 05, 2020
Thrombolex is Honored by Receiving Temple University’s Prestigious President’s Spin-Out Award
Temple University President, Richard Englert, and Vice President for Research, Michele Masucci, gathered colleagues to honor the University’s top inventors, and distinguished researchers at the third annual President’s Innovation Award Gala. Fueled by more than $279 million in annual... - February 19, 2020
Thrombolex, Inc. Announces First Patient Enrolled in Early Feasibility & Safety Study Using the Bashir™ Endovascular Catheter for Pulmonary Embolism
Thrombolex, Inc. today announced the enrollment of the first patient in their Early Feasibility and Safety Study, investigating the Bashir™ Endovascular Catheter for the treatment of submassive pulmonary embolism (PE). The device was designed to quickly and safely dissolve thrombus and... - July 29, 2019